Monitoring Anticoagulant Therapy with PT and aPTT

Introduction to Anticoagulant Monitoring

The American College of Cardiology recommends PT with INR for monitoring vitamin K antagonists (VKAs) like warfarin, while aPTT is the standard test for monitoring unfractionated heparin (UFH) therapy 1, 2
PT with INR is the appropriate test for monitoring VKAs as it responds to the reduction of three vitamin K-dependent clotting factors (FII, FVII, and FX) 1
The International Normalized Ratio (INR) was established to standardize PT assay results across different thromboplastin reagents 1

Target INR range for most indications is 2.0-3.0, as recommended by the American College of Chest Physicians 3
aPTT is the most widely used laboratory test for monitoring UFH therapy, with a target range of 1.5-2.5 times the control value 1, 4
First check should be performed 2-3 hours after starting UFH infusion, with at least daily monitoring thereafter, as suggested by the Anaesthesia journal 5
Anti-Xa activity can also be used to monitor UFH and may be more efficient in achieving therapeutic range compared to aPTT, but has less clinical expertise in interpretation 1

Routine monitoring is not required for DOACs like dabigatran, apixaban, rivaroxaban, and edoxaban due to predictable pharmacokinetics, according to the American College of Chest Physicians 3, 7, 8
If assessment is needed, the ecarin clotting time (ECT) shows a linear dose-response for dabigatran, but is not widely available 3
A normal thrombin time (TT) excludes clinically relevant dabigatran levels, as recommended by the Journal of the American College of Cardiology 6
Anti-Xa assays calibrated with the specific drug should be used for monitoring factor Xa inhibitors like apixaban, rivaroxaban, and edoxaban 6

For elderly trauma patients on anticoagulants, routine coagulation assays including aPTT, TT, PT, INR, and anti-Xa levels should be performed to assess anticoagulant exposure, as suggested by the World Journal of Emergency Surgery 2
PT-INR measurements are excellent for trauma patients using VKAs, according to the World Journal of Emergency Surgery 1
For DOACs, specific quantitative assays like ECT, dilute thrombin time (dTT), and anti-Xa inhibitor tests can accurately determine plasma concentrations, but are not readily available in all hospitals 2

For dabigatran, a normal TT excludes clinically relevant levels, as recommended by the Journal of the American College of Cardiology 6
For apixaban, edoxaban, and rivaroxaban, anti-FXa assays calibrated with the specific drug are preferred for quantitation, according to the Journal of the American College of Cardiology 6